GLPwatch
Papers (10401)
Page 50 of 174, ranked by citation count.
- Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management.
- Exenatide ameliorates hydrogen peroxide-induced pancreatic β-cell apoptosis through regulation of METTL3-mediated m<sup>6</sup>A methylation.
- Liraglutide Attenuates Myocardial Fibrosis via Inhibition of AT1R-Mediated ROS Production in Hypertensive Mice.
- Anti-inflammatory and pro-healing impacts of exendin-4 treatment in Zucker diabetic rats: Effects on skin wound fibroblasts.
- Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.
- Effect of Liraglutide on Corneal Kindling Epilepsy Induced Depression and Cognitive Impairment in Mice.
- Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis.
- Exendin-4 relieves the inhibitory effects of high glucose on the proliferation and osteoblastic differentiation of periodontal ligament stem cells.
- Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus.
- Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes.
- Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists.
- Intranasal administration of Exendin-4 antagonizes Aβ31-35-induced disruption of circadian rhythm and impairment of learning and memory.
- Nephrotoxicity in mice after repeated imaging using 111In-labeled peptides.
- Incretin-based therapies for the treatment of obesity-related diseases.
- GLP-1R Agonist Liraglutide Attenuates Inflammatory Reaction and Neuronal Apoptosis and Reduces Early Brain Injury After Subarachnoid Hemorrhage in Rats.
- Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis.
- The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes.
- Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder.
- The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
- Determining predictors of response to exenatide in type 2 diabetes.
- Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 Analogs.
- Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis.
- Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury.
- Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life.
- Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide.
- Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.
- Effect of water on exenatide acylation in poly(lactide-co-glycolide) microspheres.
- Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.
- Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.
- The effect of liraglutide on the proliferation, migration, and osteogenic differentiation of human periodontal ligament cells.
- Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance.
- Uncovering CNS access of lipidated exendin-4 analogues by quantitative whole-brain 3D light sheet imaging.
- Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.
- Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.
- Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases.
- GLP-1-based therapies and the exocrine pancreas: more light, or just more heat?
- Exendin-4-encapsulated dissolving microneedle arrays for efficient treatment of type 2 diabetes.
- Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism.
- GLP-1 based agents and acute pancreatitis : drug safety falls victim to the three monkey paradigm.
- Exenatide Attenuates Obesity-Induced Mitochondrial Dysfunction by Activating SIRT1 in Renal Tubular Cells.
- Liraglutide: from clinical trials to clinical practice.
- Transient neonatal diabetes mellitus gene Zac1 impairs insulin secretion in mice through Rasgrf1.
- Liraglutide and Exercise Synergistically Attenuate Vascular Inflammation and Enhance Metabolic Insulin Action in Early Diet-Induced Obesity.
- Effect of GLP-1 Receptor Agonists in the Cardiometabolic Complications in a Rat Model of Postmenopausal PCOS.
- Species differences in pancreatic binding of DO3A-VS-Cys<sup>40</sup>-Exendin4.
- Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
- Purification of family B G protein-coupled receptors using nanodiscs: Application to human glucagon-like peptide-1 receptor.
- Circulating microRNA-375 as biomarker of pancreatic beta cell death and protection of beta cell mass by cytoprotective compounds.
- Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients.
- Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss.
- Semaglutide utilization associated with reduced 90-day postoperative complications following single-level posterior lumbar fusion for patients with type II diabetes.
- Pharmacological Treatment for Obesity in Adults: An Umbrella Review.
- GLP‑1 receptor agonist protects palmitate-induced insulin resistance in skeletal muscle cells by up-regulating sestrin2 to promote autophagy.
- Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity.
- Composite endpoints in trials of type-2 diabetes.
- Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study.
- A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus.
- Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats.
- Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
- Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats.